drugset / Trial / NCT05406700
Niraparib In Recurrent IDH 1/2 Gliomas
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, two-arm, open-label, phase 0 trial to assess intratumoral pharmacokinetics and pharmacodynamics of niraparib in subjects with progressive IDH1 or IDH2 mutant glioma. \- This research study involves an experimental treatment called Niraparib.
Timeline
- Start
- 2023-05-18
- Primary completion
- 2026-07
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | — | Oral |